Investor Fact Sheet

Summer 2024
Nasdaq: CTXR

Citius Pharmaceuticals, Inc. is a diversified late-stage biopharmaceutical company with multiple near-term catalysts:

- FDA decision on BLA submission for rare cancer drug anticipated August 13, 2024
- 2024 commercialization of first product, LYMPHIR, planned if approved
- Publication of positive Phase 3 trial results for novel antibiotic lock solution designed to salvage catheters in patients with catheter-related blood stream infections expected
- Spin-off of oncology subsidiary to form separate publicly listed company underway

DIVERSIFIED PIPELINE

MINO-LOK®

A novel first and only antibiotic lock solution to salvage central venous catheters (CVCs) in patients with catheter-related bloodstream infections.

- **Status:** Positive Topline results with full data analysis underway; engaging with FDA next steps in Mino-Lok program; eligible for FDA priority review of NDA once submitted.
- **Positive Phase 3 Topline results**: Achieved primary and secondary endpoints; Mino-Lok outperforms hospital-specific anti-infective lock solutions.
- **Market:** Catheter-related bloodstream infection (CRBSI) and central line-associated bloodstream infection (CLABSI) market total estimated at >$1.8B worldwide.
- **First and only advantage:** No current FDA-approved or investigational products for salvaging infected CVCs; potential to change standard of care.

LYMPHIR™

The only systemic therapy to work on the IL-2 receptor in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), both as a targeted therapy that eliminates malignant T cells in the skin and as an immunotherapy that depletes Tregs.

- **Status:** Prescription Drug User Fee Act (PDUFA) target action date August 13, 2024; 2H 2024 commercialization planned, if approved.
- **Positive Phase 3 results:** 36% objective response rate in heavily pretreated (median of 4 prior therapies; significant reduction in skin tumors for 84% of patients.
- **Market:** Estimated $300-$400+M addressable U.S. market with additional growth opportunities; historically, new market entrants have expanded the size of the market.
- **Market advantage:** No curative therapeutics on the market. Only IL-2R targeted therapy.

HALO-LIDO

A proprietary topical cream formulation intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids.

- **Status:** Dose for Phase 3 trial selected; ongoing engagement with FDA.
- **Positive Phase 2b results:** Meaningful reduction in symptom severity when compared to individual components alone.
- **Market:** +10M patients report symptoms of hemorrhoidal disease; 1/3 seek physician treatment.1
- **First and only advantage:** No FDA-approved prescription hemorrhoid products available.

INVESTMENT HIGHLIGHTS

- **Strong Momentum in 2024.** Three potentially transformative near-term catalysts for late-stage assets.
- **Diversified Portfolio of Potential First-in-Class Products.** Critical care treatments for three large and underserved health concerns; unique commercial advantages.
- **Attractive Multi-Billion Dollar Global Market Opportunities.** Adjunctive cancer care, infectious disease, and gastrointestinal disease.
- **Proven Leadership Team.** Extensive pharma operational and value creation track record pre-Citius.
- **Strong Financial Platform.** Financial stewardship supports pipeline development and investment in long-term growth; $26.5 M invested by insiders.

BUSINESS DEVELOPMENT

CITIUS ONCOLOGY

Merger of wholly owned subsidiary with TenX Keane Acquisition (Nasdaq: TENK) to form publicly listed Citius Oncology.

- Transaction progressing, pending review by Securities and Exchange Commission (SEC) and TENK shareholder approval.
- Intended to unlock value of the Company's oncology business, which management believes is not currently priced into valuation.
- Facilitates greater access to capital markets for Citius Oncology.
- Citius to receive $675M in shares of Citius Oncology and retain ~90% equity.

ADDITIONAL LYMPHIR™ OPPORTUNITIES

LYMPHIR's differentiated mechanism-of-action may offer potential beyond CTCL. Two Investigator-initiated Phase 1 studies are underway:

- LYMPHIR in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) at the University of Pittsburgh.
- LYMPHIR given prior to lymphodepletion chemotherapy and FDA-approved CAR-Ts[2] for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma, who are at a high risk of failure of CAR-T therapy alone at the University of Minnesota.

CITIUS OFFICERS

Leonard Mazur

CHAIRMAN & CEO, CO-FOUNDER

Myron Holubiak

EXECUTIVE VICE CHAIRMAN, CO-FOUNDER

Jamie Bartushak

CFO & CHIEF BUSINESS OFFICER, EVP

Myron Czuczman, MD

CHIEF MEDICAL OFFICER, EVP

STOCK DATA

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
$0.64 (6/12/24)	$0.60 - $1.40	1.5M	180.6M	$116.7M

[1]MAYO CLINIC Hemorrhoidal disease: Diagnosis and management

[2]KYMRIAH, YESCARTA, and BREYANZI

Citius Pharmaceuticals, Inc.

11 Commerce Drive, First Floor
Cranford, NJ 07016
www.citiuspharma.com

Investor Relations Contact

Ilanit Allen

(908) 967-6677 x113
ir@citiuspharma.com